Argos Therapeutics Inc (NASDAQ: ARGS) is having an overwhelmingly strong day in the market today, and for good reason. The company announced a license agreement that led to excitement among investors, sending the stock screaming for the top. Today, we’ll talk about the news, what we’re seeing from ARGS as a result, and what we’ll be watching for ahead.
ARGS Gains On License Agreement
As mentioned above, Argos Therapeutics is having an overwhelmingly strong start to the trading session this morning after announcing that it has entered into a license agreement. In a press release recently issued by the company, ARGS said that it has entered into an option agreement with Pharmstandard International, S.A. and Actigen Limited. Under the terms of the agreement the company has an option to license a group of fully human anti-PD1 monoclonal antibodies, also known as PD1 checkpoint inhibitors, and related technology.
In a recent presentation at the ASCO-SITC Clinical Immuno-Oncology Symposium, ARGS announced that results of a preclinical study of a murine analogue of Rocapuldencel-T (Roca-T) in various combinations with murine PD1 monoclonal antibody and sunitinib in a mouse model of renal cell carcinoma proved promising results. This agreement ultimately shows that the company is working to rapidly further development of this potentially revolutionary treatment. In a statement, Charles Nicolette, CSO at ARGS, had the following to offer:
Data from this study support the rationale for combining dendritic cell therapy with a PD1 checkpoint inhibitor in the treatment of renal cell carcinoma… These data also demonstrate the importance of the administration sequence for active immunotherapy with a murine analogue of Roca-T and a PD1 checkpoint inhibitor, along with sunitinib, and suggest that the cellular immune response must be initiated and established prior to administration of anti-mPD1 and sunitinib in order to achieve synergy in this murine model of mRCC.
The above statement was followed up by Jeff Abbey, President and CEO at ARGS. Here’s what he had to offer:
We are pleased to have secured an option to license a group of fully human PD1 antibodies from Pharmstandard and Actigen. Provided sufficient funding is available, we expect to exercise this option and undertake the necessary preclinical studies in order to initiate clinical development of Roca-T in combination with a PD1 antibody.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!